Yin You

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

Robert E. Kalb, David Fiorentino, Mark Lebwohl et al. · JAMA Dermatology · 2015 · 372 citations

Medicine, Dermatology, Pharmacotherapy +17

Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

Richard G. Langley, Mark Lebwohl, Gerald G. Krueger et al. · British Journal of Dermatology · 2014 · 203 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Arthur Kavanaugh, L. Puig, Alice B. Gottlieb et al. · Annals of the Rheumatic Diseases · 2016 · 158 citations

Medicine, Pharmacotherapy, Musculoskeletal Medicine +14

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Alexa B. Kimball, Philippe Szapary, Ulrich Mrowietz et al. · Journal of the American Academy of Dermatology · 2011 · 128 citations

Medicine, Clinical Sciences, Dermatology +11

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

Kenneth B. Gordon, April W. Armstrong, Chenglong Han et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 93 citations

Medicine, Pharmacology, Pharmacotherapy +14